<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03128138</url>
  </required_header>
  <id_info>
    <org_study_id>2016L04321</org_study_id>
    <nct_id>NCT03128138</nct_id>
  </id_info>
  <brief_title>Single Ascending Dose Study of Safety and Tolerability of SPH3127 Tablet in Chinese Healthy Volunteers</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Describe Pharmacokinetics/Pharmacodynamics, and the Safety and of SPH3127 Tablet in Chinese Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Pharmaceuticals Holding Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Pharmaceuticals Holding Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. To evaluate safety, tolerability and pharmacokinetics (PK) and pharmacodynamics (PD)
           characteristics of SPH3127 dose escalation, a single oral dose in Chines healthy
           volunteers.

        2. To explore the appropriate dose and provide the basis for the subsequent clinical
           trials.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      48 healthy volunteers will participate in this trial. Participants will be divided into 6
      group, 25mg，50mg，100mg，200mg，400mg and 800mg. In each group, 6 participants will take SPH3127
      tablet, while 2 participants will take placebo randomly. Safety data and PK/PD data will be
      collected as protocol described.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of safety parameters [adverse events, laboratory data, vital signs, and ECG]</measure>
    <time_frame>10 days</time_frame>
    <description>adverse events, laboratory data, vital signs, and ECG et al.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter 1 [Cmax]</measure>
    <time_frame>2 days</time_frame>
    <description>Peak plasma concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PD parameter 1 [Inhibition of Renion Activity (%)]</measure>
    <time_frame>2 days</time_frame>
    <description>Inhibition of Renion Activity (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PD parameter 2 [Blood pressure (mmHg)]</measure>
    <time_frame>2 days</time_frame>
    <description>Blood pressure (mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter 2 [tmax]</measure>
    <time_frame>2 days</time_frame>
    <description>time to peak plasma concentration (tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter 3 [AUC]</measure>
    <time_frame>2 days</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC)</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>25 mg SPH3127 tablet-Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 Volunteers, Single dose of SPH3127 tablet, 25mg, po. 1 tablet.
2 Volunteers, Single dose of Placebo tablet, 25mg, po. 1 tablet.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>50 mg SPH3127 tablet-Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 Volunteers, Single dose of SPH3127 tablet, 50mg, po. 1 tablet.
2 Volunteers, Single dose of Placebo tablet, 50mg, po. 1 tablet.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100 mg SPH3127 tablet-Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 Volunteers, Single dose of SPH3127 tablet, 100mg, po. 1 tablet.
2 Volunteers, Single dose of Placebo tablet, 100mg, po. 1 tablet.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200 mg SPH3127 tablet-Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 Volunteers, Single dose of SPH3127 tablet,100mg, po. 2 tablet.
2 Volunteers, Single dose of Placebo tablet, 100mg, po. 2 tablet.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>400 mg SPH3127 tablet-Dose 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 Volunteers, Single dose of SPH3127 tablet,100mg, po. 4 tablet.
2 Volunteers, Single dose of Placebo tablet, 100mg, po. 4 tablet.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>800 mg SPH3127 tablet-Dose 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 Volunteers, Single dose of SPH3127 tablet,100mg, po. 8 tablet.
2 Volunteers, Single dose of Placebo tablet, 100mg, po. 8 tablet.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPH3127</intervention_name>
    <description>Drug: SPH3127 Tablet
Drug: Placebo Tablet</description>
    <arm_group_label>25 mg SPH3127 tablet-Dose 1</arm_group_label>
    <arm_group_label>50 mg SPH3127 tablet-Dose 2</arm_group_label>
    <arm_group_label>100 mg SPH3127 tablet-Dose 3</arm_group_label>
    <arm_group_label>200 mg SPH3127 tablet-Dose 4</arm_group_label>
    <arm_group_label>400 mg SPH3127 tablet-Dose 5</arm_group_label>
    <arm_group_label>800 mg SPH3127 tablet-Dose 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adults,age &gt;=18 years.Single gender should no less than a third of total
             subjects in each group.

          -  BMI should be18 to 24 kg/m2 (including threshold), allowing the lowest weight 50 kg
             (including threshold) for the male and 45 kg (including threshold) for the female.

          -  understand details of significance, benefit, inconvenience and potential danger of the
             research program, voluntarily signed informed consent.

        Exclusion Criteria:

          -  during pregnancy, nursing mothers, and plans to test in the first 6 months (grant)
             pregnant;

          -  abnormal results in physical examination, laboratory examination and have clinical
             significance (such as: liver function examination - aspartate aminotransferase
             (AST)/alanine aminotransferase (ALT) is more than 1.5 times of the upper limit of
             normal).

          -  with cardiovascular, liver, kidney, gastrointestinal, nervous system, blood system and
             familial blood disease, thyroid dysfunction or abnormal mental illness;

          -  has a history of drug allergy and allergic constitution;

          -  took birth control pills within 6 weeks;

          -  used any drugs (including Chinese herbal medicine) within 1 week;

          -  participated in blood donation within 2 months ;

          -  participated in any drug clinical trials (as subjects) within three months;

          -  any positive result in virus serology check: human immunodeficiency virus antigen
             antibody (HIV Ag/Ab) 、hepatitis c virus (HCV) - IgG antibody to IgG, hepatitis b
             surface antigen (HBsAg) and treponema pallidum antibody (TP);

          -  addicted to cigarettes, alcohol, drink coffee, strong tea and drug abuse;

          -  researchers think that exists any unfavorable factors to participate in the test.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>HONG MIAO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Pharmaceuticals Holding Co., Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>WENHONG XIA</last_name>
    <phone>13524703788</phone>
    <email>xiawh@sphchina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The capital medical university affiliated Beijing anzhen hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>YANG LIN</last_name>
      <email>linyang3623@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2017</study_first_submitted>
  <study_first_submitted_qc>April 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 25, 2017</study_first_posted>
  <last_update_submitted>July 16, 2017</last_update_submitted>
  <last_update_submitted_qc>July 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

